<DOC>
	<DOCNO>NCT00003862</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness chemotherapy radiation therapy treat patient stomach cancer .</brief_summary>
	<brief_title>Chemotherapy Radiation Therapy Treating Patients With Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility preoperative chemoradiotherapy patient potentially resectable adenocarcinoma stomach . - Determine pathologic response rate , curative resection rate , survival patient treat regimen . - Determine tolerability regimen patient . OUTLINE : Patients receive fluorouracil IV 24 hour day 1-21 , cisplatin IV 1 hour day 1-5 , leucovorin calcium IV 15 minute day 1 , 8 , 15 , 22 . A second course administer begin day 29 . Chemoradiotherapy begin end second course chemotherapy 1 week rest ( day 57 ) . Patients receive fluorouracil IV 24 hour 5 day week concurrently radiotherapy 5 week paclitaxel IV 3 hour weekly 5 week day 1 , 8 , 15 , 22 , 29 . Approximately 4-5 week chemoradiotherapy , patient evidence metastatic disease undergo surgical resection . Patients follow every 3 month 1 year , every 6 month 5 year , annually thereafter . PROJECTED ACCRUAL : A total 21-49 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma stomach Stage IB , II , IIIA , IIIB , IV ( T23 , N , M0 ) No lymph node metastasis outside field resection ( e.g. , supraclavicular , mediastinal , paraaortic node ) Potentially resectable May involve gastroesophageal junction , bulk tumor must stomach No distant metastases No pleural pericardial effusion No peritoneal disease diagnose laparoscopy PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 02 Life expectancy : At least 16 week Hematopoietic : Absolute granulocyte count great 2,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine le 1.5 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease No hypertension Neurologic : No cerebrovascular disease No diabetic neuropathy No mental status abnormalities Other : No uncontrolled diabetes No infection No malignancy within past 5 year except resect squamous cell basal cell skin cancer Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy stomach Surgery : No prior surgery stomach</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>stage I gastric cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
</DOC>